1223 completed, 161 terminated, 115 recruiting, 90 unknown. 1775 Phase 2, 202 Phase 1, 136 Phase 3.
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis | Phase 2 | Withdrawn | Stanford University | 2030-12-01 | 2024-12-02 | |
| Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis | Phase 2 | Not yet recruiting | Enzychem Lifesciences Corporation | 150 | 2027-05-01 | 2026-08-28 |
| Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function | Phase 2 | Not yet recruiting | Foresee Pharmaceuticals Co., Ltd. | 135 | 2027-03-01 | 2026-07-20 |
| UNC Cashew Sublingual Immunotherapy Cashew sublingual immunotherapy, Placebo sublingual immunotherapy - Cashew Nut Allergy, Tree Nut Allergies | Phase 2 | Not yet recruiting | University of North Carolina, Chapel Hill | 45 | 2027-03-01 | 2026-10-20 |
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) Benralizumab 30 MG/ML [Fasenra], Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride - DRESS Syndrome | Phase 2 | Not yet recruiting | University Hospital, Lille | 96 | 2027-01-06 | 2026-05-15 |
| Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma | Phase 2 | Not yet recruiting | Indiana University | 30 | 2027-01-01 | 2026-02-27 |
| Nebulized Ketamine for Severe Asthma Attacks in Children Ketamine (1 mg/kg), Placebo - Asthma Acute, Exacerbation of Allergic Asthma | Phase 2 | Not yet recruiting | Sultan Qaboos University | 60 | 2027-01-01 | 2026-07-27 |
| LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) Placebo, LAM-001 - Sarcoidosis Associated Pulmonary Hypertension | Phase 2 | Not yet recruiting | IRulya Therapeutics Inc. | 60 | 2026-12-01 | 2026-10-21 |
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 158 | 2026-11-06 | 2026-10-09 |
| Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis Prednisone, Compound betamethasone - Sarcoidosis, Pulmonary | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 126 | 2026-11-01 | 2026-10-15 |
| Ginger's Therapeutic Potential in Asthma Ginger Extract, Placebo - Asthma | Phase 2 | Not yet recruiting | Emily DiMango, MD | 32 | 2026-11-01 | 2026-08-28 |
| An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations XTMAB-16, Placebo - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Xentria, Inc. | 182 | 2026-10-30 | 2026-10-21 |
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis 0.5% AR100DP1, Placebo - Dermatitis Atopic | Phase 2 | Recruiting | Arjil Pharmaceuticals LLC | 40 | 2026-10-21 | 2026-11-03 |
| A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma JNJ-95597528, Placebo - Asthma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 440 | 2026-10-05 | 2026-11-03 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis LT-002-158, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 160 | 2026-10-01 | 2026-10-26 |
| Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy CM512, Placebo - Perennial Allergic Rhinitis (PAR) | Phase 2 | Not yet recruiting | Beijing Keymed Biosciences Co., Ltd. | 200 | 2026-10-01 | 2026-10-22 |
| A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream - Atopic Dermatitis (AD) | Phase 2 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 160 | 2026-09-30 | 2026-09-30 |
| A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Upadacitinib 30mg Dose, Upadacitinib Matching Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 52 | 2026-09-30 | 2026-10-06 |
Showing 20 of 1775. Sign in to see all of them.
Asthma (667) · Dermatitis, Atopic (401) · Rhinitis, Allergic (119) · Rhinitis, Allergic, Seasonal (106) · Eczema (104) · Food Hypersensitivity (63) · Chronic Urticaria (61) · Peanut Hypersensitivity (59) · Eosinophilic Esophagitis (50) · Conjunctivitis, Allergic (48) · Sarcoidosis (42) · Pruritus (40) · Angioedemas, Hereditary (35) · Rhinitis (33)
Immune System Diseases (1754) · Hypersensitivity, Immediate (1602) · Respiratory Tract Diseases (925) · Respiratory Hypersensitivity (883) · Lung Diseases (704) · Bronchial Diseases (674) · Lung Diseases, Obstructive (668) · Skin and Connective Tissue Diseases (578) · Skin Diseases (548) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (458) · Genetic Diseases, Inborn (452) · Skin Diseases, Genetic (409) · Skin Diseases, Eczematous (407) · Dermatitis (396)
Omalizumab (46) · Fluticasone (40) · dupilumab (32) · montelukast (31) · Albuterol (29) · Formoterol Fumarate (29) · Budesonide (27) · Mometasone Furoate (19) · Sodium Chloride (19) · Beclomethasone (17) · Cholecalciferol (11) · benralizumab (11) · fluticasone furoate (11) · Prednisolone (10) · Saline Solution (10)
GlaxoSmithKline (77) · Novartis Pharmaceuticals (65) · AstraZeneca (42) · National Institute of Allergy and Infectious Diseases (NIAID) (34) · Boehringer Ingelheim (28) · Pfizer (28) · Chiesi Farmaceutici S.p.A. (24) · Johns Hopkins University (23) · Sanofi (21) · Genentech, Inc. (19) · University of North Carolina, Chapel Hill (19) · Regeneron Pharmaceuticals (17) · Keymed Biosciences Co.Ltd (15) · Merck Sharp & Dohme LLC (15) · MedImmune LLC (14)
United States (866) · Germany (322) · Canada (295) · United Kingdom (217) · Poland (205) · China (138) · Spain (123) · France (108) · Australia (99) · Hungary (98) · Japan (98) · Czechia (90) · Bulgaria (87) · Netherlands (79) · South Korea (74)
Wesley Burks, MD (11) · Robert Wood, MD (10) · Dave Singh, MD (8)
PMID 27881132, PMID 36326435, PMID 38814736, PMID 39393433, PMID 36408587, PMID 36472162, PMID 19001265, PMID 19748656, PMID 21356110, PMID 24010736, PMID 24184147, PMID 24836393, PMID 25006719, PMID 25445859, PMID 25609353, PMID 26001563, PMID 26283085, PMID 26704701, PMID 28639856, PMID 28758192, PMID 29656145, PMID 30978404, PMID 33006765, PMID 33217063, PMID 33305842, PMID 33310179, PMID 34089147, PMID 34379802, PMID 34389504, PMID 34773261, PMID 35636689, PMID 36253275, PMID 36440464, PMID 36718018, PMID 36853224, PMID 39035788, PMID 39077906, PMID 39575597, PMID 41615410, PMID 11398072, PMID 12384926, PMID 12668793, PMID 12877429, PMID 14619332, PMID 14674933, PMID 15001284, PMID 15119583, PMID 15201414, PMID 15313870, PMID 15334472
2009 (21), 2018 (21), 2023 (15), 2014 (14), 2025 (14), 2015 (12), 2016 (12), 2019 (10), 2008 (9), 2017 (8), P01HL158507 (3), R01AT004435 (3), R01HL135235 (3), U19AI066738 (3), 2004 (2)